首页> 美国卫生研究院文献>Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America >Incidence of Acute Kidney Injury Among Critically Ill Patients With Brief Empiric Use of Antipseudomonal β-Lactams With Vancomycin
【2h】

Incidence of Acute Kidney Injury Among Critically Ill Patients With Brief Empiric Use of Antipseudomonal β-Lactams With Vancomycin

机译:短暂经验性使用抗假性β-内酰胺与万古霉素治疗的重症患者的急性肾损伤发生率

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Nephrotoxins contribute to 20%–40% of acute kidney injury (AKI) cases in the intensive care unit (ICU). The combination of piperacillin-tazobactam (PTZ) and vancomycin (VAN) has been identified as nephrotoxic, but existing studies focus on extended durations of therapy rather than the brief empiric courses often used in the ICU. The current study was performed to compare the risk of AKI with a short course of PTZ/VAN to with the risk associated with other antipseudomonal β-lactam/VAN combinations.
机译:在重症监护病房(ICU)中,肾毒素占急性肾损伤(AKI)病例的20%–40%。哌拉西林-他唑巴坦(PTZ)和万古霉素(VAN)的组合已被确定具有肾毒性,但现有研究集中在延长治疗时间上,而不是在ICU中经常使用的短暂经验疗程。进行本研究的目的是将短暂PTZ / VAN疗程的AKI风险与其他抗伪β-内酰胺/ VAN组合的风险进行比较。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号